Vericel Corporation

VCEL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $16.5M $10.4M $-3.2M $-16.7M $-7.5M $2.9M $-9.7M $-8.1M
Depreciation & Amortization $11.5M $5.5M $4.6M $4.0M $3.0M $2.4M $1.7M $1.4M
Depreciation $10.9M $4.9M $4.0M $4.0M $3.0M $2.4M $1.7M $1.4M
Amortization — — — — — — — —
Stock-Based Compensation $38.8M $36.5M $32.3M $37.2M $34.3M $13.8M $13.2M $7.2M
Net Cash from Operating Activities $51.9M $58.2M $35.3M $17.7M $29.0M $17.6M $-7.2M $-412.0K
Investing Activities
Capital Expenditures $27.2M $64.0M $20.0M $7.6M $7.9M $2.6M $2.6M $2.7M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-43.9M $-79.0M $-3.1M $-36.2M $-3.5M $-17.2M $10.6M $-67.0M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $7.1M $19.1M $3.6M $1.0M $9.2M $6.4M $5.3M $58.9M
Net Change in Cash $15.0M $-1.8M $35.8M $-17.5M $34.7M $6.9M $8.7M $-8.6M
Free Cash Flow $24.7M $-5.8M $15.3M $10.1M $21.1M $14.9M $-9.8M $-3.1M
← Newer Page 1 of 3 Older →